Indication intelligence, analysis and sector perception

The Biostage Chronicles: dispose and disregard, fit for the barrel

January 11, 2022

Old news as regurgitated, in a recent press release “New Paper Shows Biostage's Esophageal Implant Regenerates the Esophagus in Piglets” on 1/10. For the record, BSTG CAN’T treat birth defects in the esophagus in babies until they complete trials from a two (2) year old IND which have yet to start.

RegMed Investors (RMi): The week in review …

December 4, 2021

A mixed week of November leaving and December beginning. As we end November with one (1) negative and one (1) positive session while the first three (3) sessions of December exhibited two (2) negative closes and one (1) positive. Sector equities are not easy to buy in this environment as … November ended with 1 holiday 5 positive and 16 negative close to date Key metric this week; The CBOE volatility index, the VIX fear gauge, was higher 30.96 after Thursday’s 27.95 after Wednesday’s 31.12, Tuesday’s 27.19 and Monday’s 22.96. Key factors: “The uncertainty regarding Omicron is high, but coupled with the disappointing jobs number and investors decided to dump (shares) in front of the weekend.” <read more>

Chinook Therapeutics (KDNY) prices an upsized offering at $14.00 per share

November 9, 2021

KDNY closed up +$0.32 to $14.51 after Monday's -$1.77 with an aftermarket indication of +$0.24 or +1.65% Offer and sell 7,828,572 shares of its common and 3,571,428 warrants expecting $159.6 million in proceeds ... Sell Into Strength ... SVB Leerink and Evercore ISI are acting as joint book-running managers for the proposed offering. Oppenheimer & Co., Wedbush PacGrow and H.C. Wainwright & Co. are acting as lead managers for the proposed offering.